NICE approval for adalimumab in Crohn's disease

The UK's drug guidance body has issued new advice on the use of two TNF-alpha inhibitors in Crohn's disease.

It is estimated that around 60,000 people in the UK have Crohn’s disease (shown here on light micrograph), with approximately 3,000 (5%) having the most severe form | Photo: SPL
It is estimated that around 60,000 people in the UK have Crohn’s disease (shown here on light micrograph), with approximately 3,000 (5%) having the most severe form | Photo: SPL

Adalimumab is now recommended as a treatment option for people with severe, active Crohn's disease.

Infliximab continues to be recommended for adults with active, fistulising disease, and for adults and children from the age of 6 years with severe, active disease. However, NICE now advises that infliximab should be given in a planned course until treatment failure, or for up to 12 months if sooner. Continued treatment is indicated only if there is clear evidence of ongoing active disease.

Use of both adalimumab and infliximab is restricted to patients who have failed to respond to, are intolerant of, or are unable to take more commonly used treatment options. Treatment should normally be started with the less expensive agent.

NICE guidance on infliximab and adalimumab for Crohn's disease

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in